ArticleProceedings of the National Academy of Sciences of the United States of America2006
TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 87 citations in OpenAlex.
- Safety and immunogenicity of PPV-06, an active anti-IL-6 immunotherapy targeting low-grade inflammation against knee osteoarthritis: a randomized, double-blind, placebo-controlled, clinical phase 1 study.Nature communications · 2025Trial
- Trial
- Impact of JAK-inhibition on pain and biphasic P2X7R expression on CD4Scientific reports · 2026Article
- Immunization with detoxified TNFα elicits neutralizing antibodies and ameliorates inflammatory shock and autoimmune arthritis in mice.Frontiers in immunology · 2026Article
- Intra-articular sustained-release colchicine is efficacious in an inflammatory arthritis rat model.RMD open · 2025Article
- Vaccines for immune tolerance against autoimmune disease.Advanced drug delivery reviews · 2023Review
- Vaccination therapy for inflammatory bowel disease.Human vaccines & immunotherapeutics · 2023Review
- Molecular Peptide Grafting as a Tool to Create Novel Protein Therapeutics.Molecules (Basel, Switzerland) · 2023Review
- A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™.Frontiers in cardiovascular medicine · 2023Review
- Immunogenicity profile in African green monkeys of a vaccine candidate based on a mutated form of human Interleukin-15.BMC immunology · 2021Article
- Therapeutic Potential of Anti-Interferon α Vaccination on SjS-Related Features in the MRL/lpr Autoimmune Mouse Model.Frontiers in immunology · 2021Article
- Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis.Frontiers in immunology · 2020Article
- Peptide-Based Vaccination Therapy for Rheumatic Diseases.Journal of immunology research · 2020Review
- Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers.Biomaterials · 2017Article
- Regenerative medicine: Breaking Prometheus's curse for cartilage regeneration.Nature reviews. Rheumatology · 2017Article
- Arthritis models: usefulness and interpretation.Seminars in immunopathology · 2017Review
- CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.Clinical reviews in allergy & immunology · 2017Review
- Tumor Necrosis Factor-Alpha Targeting Can Protect against Arthritis with Low Sensitization to Infection.Frontiers in immunology · 2017Article
- IL-1 Vaccination Is Suitable for Treating Inflammatory Diseases.Frontiers in pharmacology · 2017Article
- Active immunization with human interleukin-15 induces neutralizing antibodies in non-human primates.BMC immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The proinflammatory cytokine TNFalpha is a potent mediator of septic shock and a therapeutic target for chronic inflammatory pathologies including rheumatoid arthritis and Crohn's disease. As an alternative to anti-human TNFalpha (hTNFalpha) mAbs and other hTNFalpha blocker approved drugs, we developed an active anti-hTNFalpha immunotherapy, based on a vaccine comprised of a keyhole limpet hemocyanin-hTNFalpha heterocomplex immunogen (hTNFalpha kinoid) adjuvanted in incomplete Freund's adjuvant. In mice transgenic for hTNFalpha (TTg mice), hTNFalpha kinoid vaccination elicited high titers of Abs that neutralized hTNFalpha bioactivities but did not result in a cellular response to hTNFalpha. The vaccine was safe and effective in two experimental models. Kinoid-immunized but not control TTg mice resisted hTNFalpha-driven shock in one model and were prevented from spontaneous arthritis, inflammatory synovitis, and articular destruction in a second model. These data demonstrate an anti-cytokine induction of autoimmune protection against both acute and chronic hTNFalpha exposure. They show that active vaccination against a human cytokine can be achieved, and that the immune response can be effective and safe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.